The Ministry of Health, Labor and Welfare (MHLW) on December 18 presented a proposal to define the scope of products…
BUSINESS
Sakigake: Now and Future (2) - Shionogi Aims to Submit Application for Novel Flu Drug as Early as FY2017
One of the products that has been selected for expedited review under the sakigake fast-track review system is the CAP-dependent endonuclease inhibitor S-033188, an influenza therapy with a novel mechanism of action being developed by Shionogi. It inhibits the replication…
To read the full story
Related Article
- Sakigake: Now and Future (5) - BioCryst’s BCX7353 Would Be Japan’s 1st Drug for Preventing Angioedema Attacks
April 4, 2016
- Sakigake: Now and Future (4) - MSD’s Anti-PD-1 Antibody Gets Sakigake Designation for Gastric Cancer, While Opdivo also Under Development for Same Indication
March 2, 2016
- Sakigake: Now and Future (3) - Astellas’s FLT3 Inhibitor for AML Receives Designation, but Other Companies Trailing
February 19, 2016
- Sakigake: Now and Future (1) - Topical Sirolimus on Track for Application in 2018 for 1st-in-World Indication
February 4, 2016
BUSINESS
- Astellas Snags Rights to Sangamo’s AVV Capsid for Neurological Diseases
December 20, 2024
- Xocova to Be Re-Filed in South Korea with Additional Data
December 20, 2024
- JCR Commences PIII Study for Once-Weekly Growth Hormone Therapy
December 20, 2024
- Insomnia Med Quviviq Now Available in Japan: Nxera/Shionogi
December 20, 2024
- PeptiDream Gets Milestone from Novartis on PI Launch
December 20, 2024
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
Will an “off-year” drug price revision happen in April 2025 or not? Over the last week, expectations have been up…
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…